National Institute on Drug Abuse; Notice of Closed Meetings, 29682-29683 [2023-09704]
Download as PDF
<![CDATA[
29682
Federal Register / Vol. 88, No. 88 / Monday, May 8, 2023 / Notices
of having their full effect if received
within 60 days of the date of this
publication.
To
obtain a copy of the data collection
plans and instruments, submit
comments in writing, or request more
information on the proposed project,
contact: Diane Kreinbrink, Program
Manager, Office of Management Policy
and Compliance, National Cancer
Institute, 9609 Medical Center Drive,
Room 2W446, Bethesda, Maryland,
20892 or call non-toll-free number (240)
276–7283 or email your request,
including your address to:
diane.kreinbrink@nih.gov. Formal
requests for additional plans and
instruments must be requested in
writing.
FOR FURTHER INFORMATION CONTACT:
Section
3506(c)(2)(A) of the Paperwork
Reduction Act of 1995 requires: written
comments and/or suggestions from the
public, and affected agencies are invited
to address one or more of the following
points: (1) Whether the proposed
collection of information is necessary
for the proper performance of the
function of the agency, including
whether the information will have
practical utility; (2) The accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used; (3)
Ways to enhance the quality, utility, and
clarity of the information to be
collected; and (4) Ways to minimize the
SUPPLEMENTARY INFORMATION:
outcome metrics where appropriate and
applicable. This input should provide
meaningful information that can be used
to identify strengths and areas that need
improvement. Reports developed from
the review or evaluation may be
presented by the IC Director to the IC’s
Advisory Council or Board, to other IC
or NIH leadership (such as the Deputy
Director for Intramural Research and the
NIH Director), or to program
participants or the broader public. Such
reports may include recommendations
and proposed actions to address areas
for improvement. In public or broadly
shared reports, any sensitive
information in the reviews or
evaluations will be summarized and
presented in aggregate.
This clearance will allow direct
assessment and measurement of the
customer/respondent base for
participation in and satisfaction with
NIH programs, products, and services.
The clearance will also enable offices to
assess participants’ experience and
accomplishments during or since
participation and their preferences for
existing and future programming,
products, and services. The information
collected using these tools informs and
supports budgeting, program
management and design, program
planning, results reporting, information
dissemination, and outreach initiatives.
OMB approval is requested for 3
years. There are no costs to respondents
other than their time. The total
estimated annualized burden hours are
3,375.
burden of the collection of information
on those who are to respond, including
the use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology.
Proposed Collection Title: Generic
Clearance for the Collection of Customer
Participation and Performance
Management with NIH Programs,
Products, and Services (NIH), 0925–
XXXX: Expiration Date XX/XX/XXXX,
NEW, National Institutes of Health
(NIH).
Need and Use of Information
Collection: Evaluating the effectiveness
of leadership, programs, and services is
essential for the vitality of any
institution. Leadership review at NIH
focuses on the productivity of the IC,
management of resources and budget
allocations, training activities, and
influence on dimensions of diversity,
inclusion, promotion of investigators
and staff (including NIH Equity
Committee (NEC) reports), and positive
workforce culture.
Program and service reviews may
focus on operational performance;
outputs, outcomes, and impacts; policy
compliance, stewardship, diversity,
equity, and inclusion. Both types of
reviews and evaluations may solicit
input from IC staff and leadership (IC
Director, Deputy Director, E.O.) and
relevant program participants and
stakeholders about the program’s
effectiveness, leader, or process. They
may include comparisons with other ICs
or programs, external benchmarks, and
ESTIMATED ANNUALIZED BURDEN HOURS
Type of respondent
Individuals, Households, Private Sector, State
Government, Local Government, Tribal Government, or Federal Government.
ddrumheller on DSK120RN23PROD with NOTICES1
Totals .............................................................
Dated: May 3, 2023.
Diane Kreinbrink,
Project Clearance Liaison, National Cancer
Institute, National Institutes of Health.
[FR Doc. 2023–09708 Filed 5–5–23; 8:45 am]
BILLING CODE 4140–01–P
Number of
respondents
Form name
Performance Measurement.
21:48 May 05, 2023
Jkt 259001
Total burden
hour
500
1
30/60
250
Interviews .....................
Program Reviews .........
Surveys .........................
Focus Groups ...............
1,000
500
5,000
500
1
1
1
1
1
45/60
15/60
1
1,000
375
1,250
500
.......................................
........................
7,500
........................
3,375
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meetings
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
VerDate Sep<11>2014
Average
burden per
response
(in hours)
Number of
responses per
respondent
PO 00000
Frm 00062
Fmt 4703
Sfmt 4703
amended, notice is hereby given of the
following meeting.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications
and/or contract proposals and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
E:\FR\FM\08MYN1.SGM
08MYN1
Federal Register / Vol. 88, No. 88 / Monday, May 8, 2023 / Notices
personal information concerning
individuals associated with the grant
applications and/or contract proposals,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; NIDA
International Program: Research and Training
Support.
Date: May 24, 2023.
Time: 10:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institute of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Preethy Nayar, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, National Institute on Drug Abuse,
NIH, 301 North Stonestreet Avenue,
Bethesda, MD 20892, (301) 443–4577,
nayarp2@csr.nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Exploratory Studies to Investigate
Mechanisms of HIV Infection, Replication,
Latency, and/or Pathogenesis in the Context
of SUD.
Date: June 12, 2023.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Soyoun Cho, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Research,
National Institute on Drug Abuse, NIH, 301
North Stonestreet Avenue, Bethesda, MD
20892, (301) 594–9460, Soyoun.cho@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
Dated: May 2, 2023.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–09704 Filed 5–5–23; 8:45 am]
BILLING CODE 4140–01–P
ddrumheller on DSK120RN23PROD with NOTICES1
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Neurological
Disorders and Stroke; Notice of Closed
Meetings
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
VerDate Sep<11>2014
21:48 May 05, 2023
Jkt 259001
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel; Clinical Trials in Neurology.
Date: May 11–12, 2023.
Time: 9:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate
cooperative agreement applications
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Virtual
Meeting).
Contact Person: Shanta Rajaram, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Activities,
NINDS/NIH, NSC, 6001 Executive Blvd.,
Suite 3208, MSC 9529, Rockville, MD 20852,
301–435–6033, rajarams@mail.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel; Phase 2 Clinical Trials in
Neurology.
Date: May 12, 2023.
Time: 2:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate
cooperative agreement applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Virtual
Meeting).
Contact Person: Iqbal Sayeed, Ph.D.
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Activities,
NINDS/NIH, NSC, 6001 Executive Blvd.,
Suite 3208, MSC 9529, Rockville, MD 20852,
301–496–9223, iqbal.sayeed@nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
29683
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Limited Competition:
Resources and Workforce Development for
the Regional Biocontainment Laboratories
(UC7 Clinical Trial Not Allowed).
Date: June 1–2, 2023.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3F30,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Scott Jakes, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3F30, Rockville, MD
20852, (240) 669–5931, jakesse@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: May 2, 2023.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–09703 Filed 5–5–23; 8:45 am]
BILLING CODE 4140–01–P
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS.)
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Dated: May 3, 2023.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
National Institute of Neurological
Disorders and Stroke; Notice of Closed
Meetings
[FR Doc. 2023–09711 Filed 5–5–23; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
National Institutes of Health
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
E:\FR\FM\08MYN1.SGM
08MYN1
]]>Agencies
[Federal Register Volume 88, Number 88 (Monday, May 8, 2023)]
[Notices]
[Pages 29682-29683]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-09704]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meetings
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5
U.S.C., as amended. The grant applications and/or contract proposals
and the discussions could disclose confidential trade secrets or
commercial property such as patentable material, and
[[Page 29683]]
personal information concerning individuals associated with the grant
applications and/or contract proposals, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; NIDA International Program: Research and Training
Support.
Date: May 24, 2023.
Time: 10:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institute of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Preethy Nayar, Ph.D., Scientific Review Officer,
Scientific Review Branch, National Institute on Drug Abuse, NIH, 301
North Stonestreet Avenue, Bethesda, MD 20892, (301) 443-4577,
[email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Exploratory Studies to Investigate Mechanisms of HIV
Infection, Replication, Latency, and/or Pathogenesis in the Context
of SUD.
Date: June 12, 2023.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Soyoun Cho, Ph.D., Scientific Review Officer,
Scientific Review Branch, Division of Extramural Research, National
Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue,
Bethesda, MD 20892, (301) 594-9460, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug
Abuse Scientist Development Award for Clinicians, Scientist
Development Awards, and Research Scientist Awards; 93.278, Drug
Abuse National Research Service Awards for Research Training;
93.279, Drug Abuse and Addiction Research Programs, National
Institutes of Health, HHS)
Dated: May 2, 2023.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2023-09704 Filed 5-5-23; 8:45 am]
BILLING CODE 4140-01-P
